Estás usando un navegador no soportado
Usar Internet Explorer está desaconsejado por problemas de seguridad. Para ver correctamente esta web, por favor use cualquier navegador moderno: Chrome, Firefox, Edge, Safari u otro de su elección.
En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias
FILTRAR POR:
322 ARTÍCULOS , VIENDO DEL 181 AL 195
Dangour AD, Whitehouse PJ, Rafferty K, Mitchell SA, Smith L, Hawkesworth S, Vellas B.
J Alzheimers Dis. 2010;22(1):205-24. doi: 10.3233/JAD-2010-090940.
Effect of an antioxidant drink on homocysteine levels in Alzheimer's patients
Morillas-Ruiz JM, Rubio-Perez JM, Albaladejo MD, Zafrilla P, Parra S, Vidal-Guevara ML.
J Neurol Sci. 2010 Dec 15;299(1-2):175-8. doi: 10.1016/j.jns.2010.08.050. Epub 2010 Sep 20.
[Therapeutic strategies for Alzheimer disease based on endoplasmic reticulum stress]
Kudo T.
Nihon Shinkei Seishin Yakurigaku Zasshi. 2010 Aug;30(4):163-8.
[Immunotherapy and Alzheimer's disease]
Arai H.
Nihon Shinkei Seishin Yakurigaku Zasshi. 2010 Aug;30(4):173-6.
Ando C, Hishinuma M.
Psychogeriatrics. 2010 Sep;10(3):131-7. doi: 10.1111/j.1479-8301.2010.00324.x. Epub 2010 Aug 28.
Evidence supporting technology-based interventions for people with early-stage Alzheimer's disease
Buettner LL, Yu F, Burgener SC.
J Gerontol Nurs. 2010 Oct;36(10):15-9. doi: 10.3928/00989134-20100831-01. Epub 2010 Sep 22.
Finding the right target for treating Alzheimer disease
Mandell BF.
Cleve Clin J Med. 2010 Oct;77(10):650. doi: 10.3949/ccjm.77b.10010.
Health economics and health policy issues in Alzheimer's disease
Rapp T.
J Nutr Health Aging. 2010 Oct;14(8):630-2. doi: 10.1007/s12603-010-0308-2.
Savings from sub-groups?: Policy guidance and Alzheimer's disease treatments
McNamee P, Vanoli A, Hutchings D, McKeith I, Bond J.
J Nutr Health Aging. 2010 Oct;14(8):664-8. doi: 10.1007/s12603-010-0313-5.
Phenserine efficacy in Alzheimer's disease
Winblad B, Giacobini E, Frölich L, Friedhoff LT, Bruinsma G, Becker RE, Greig NH.
J Alzheimers Dis. 2010;22(4):1201-8. doi: 10.3233/JAD-2010-101311.
The pharmacoeconomics of cognitive enhancers in moderate to severe Alzheimer's disease
Cappell J, Herrmann N, Cornish S, Lanctôt KL.
CNS Drugs. 2010 Nov;24(11):909-27. doi: 10.2165/11539530-000000000-00000.
Investigational medications for treatment of patients with Alzheimer disease
Potter PE.
J Am Osteopath Assoc. 2010 Sep;110(9 Suppl 8):S27-36.
Recruitment of subjects into clinical trials for Alzheimer disease
Knebl JA, Patki D.
J Am Osteopath Assoc. 2010 Sep;110(9 Suppl 8):S43-9.
Phosphodiesterase-5 inhibitors: novel weapons against Alzheimer's disease?
Sabayan B, Zamiri N, Farshchizarabi S, Sabayan B.
Int J Neurosci. 2010 Dec;120(12):746-51. doi: 10.3109/00207454.2010.520381. Epub 2010 Oct 13.
Novel drug targets based on metallobiology of Alzheimer's disease
Bandyopadhyay S, Huang X, Lahiri DK, Rogers JT.
Expert Opin Ther Targets. 2010 Nov;14(11):1177-97. doi: 10.1517/14728222.2010.525352.
Actualización mensual Regístrese para recibir los avisos de actualización
Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.